GTHX - G1 Therapeutics Inc. (GTHX) Q1 2024 Earnings Call Transcript
2024-05-01 12:04:08 ET
G1 Therapeutics, Inc. (GTHX)
Q1 2024 Earnings Conference Call
May 01, 2024 08:30 AM ET
Company Participants
Will Roberts - Investor Relations
Jack Bailey - Chief Executive Officer
Andrew Perry - Chief Commercial Officer
Raj Malik - Chief Medical Officer
John Umstead - Chief Financial Officer
Conference Call Participants
Gil Blum - Needham
Joseph Thome - TD Cowen
Laura Prendergast - Raymond James
David Nierengarten - Wedbush
Steve Bersey - H.C. Wainwright
Presentation
Operator
Good day, and thank you for standing by. Welcome to the G1 Therapeutics First Quarter 2024 Financial Results. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Will Roberts. Please go ahead.
Will Roberts
Thank you, Victor. Good morning, everyone, and welcome to the G1 conference call to discuss our first quarter 2024 financial results and business update. The press release on these financial results was issued this morning and can be found in our News section of our corporate website, g1therapeutics.com.
On this morning's call, the team will provide a business overview of the 2024 first quarter, including an update on our commercial progress and clinical programs in that period with COSELA, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. A Q&A session will follow the prepared remarks....
G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript